Zacks: BioPharmX Corporation (NASDAQ:BPMX) Given $4.63 Average Price Target by Analysts

Shares of BioPharmX Corporation (NASDAQ:BPMX) have been given an average broker rating score of 1.00 (Strong Buy) from the two brokers that provide coverage for the company, Zacks Investment Research reports. Two investment analysts have rated the stock with a strong buy recommendation.

Brokerages have set a twelve-month consensus target price of $4.63 for the company and are expecting that the company will post ($0.25) earnings per share for the current quarter, according to Zacks. Zacks has also given BioPharmX an industry rank of 62 out of 256 based on the ratings given to its competitors.

NASDAQ BPMX traded down $0.04 during trading hours on Monday, reaching $0.59. The company’s stock had a trading volume of 1,022,066 shares, compared to its average volume of 687,291. BioPharmX has a fifty-two week low of $0.51 and a fifty-two week high of $6.75. The business’s 50-day moving average price is $0.82.

BioPharmX (NASDAQ:BPMX) last issued its quarterly earnings data on Tuesday, June 11th. The company reported ($0.38) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.25) by ($0.13).

BioPharmX Company Profile

BioPharmX Corporation, a specialty pharmaceutical company, develops and commercializes novel prescription and over-the-counter (OTC) products that address dermatology and women's health markets. The company offers VI2OLET, an OTC molecular iodine dietary supplement that addresses cyclic breast discomfort, as well as alleviates the symptoms of fibrocystic breast condition (FBC).

Recommended Story: What is a put option?

Get a free copy of the Zacks research report on BioPharmX (BPMX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for BioPharmX Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioPharmX and related companies with MarketBeat.com's FREE daily email newsletter.